Free Trial
NASDAQ:DBVT

DBV Technologies Q3 2024 Earnings Report

DBV Technologies logo
$9.90 +0.13 (+1.33%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DBV Technologies EPS Results

Actual EPS
-$0.80
Consensus EPS
-$1.90
Beat/Miss
Beat by +$1.10
One Year Ago EPS
N/A

DBV Technologies Revenue Results

Actual Revenue
$1.07 million
Expected Revenue
$1.17 million
Beat/Miss
Missed by -$100.00 thousand
YoY Revenue Growth
N/A

DBV Technologies Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Wednesday, November 6, 2024
Conference Call Time
2:00AM ET

Earnings Documents

DBV Technologies Earnings Headlines

Q3 EPS Estimates for DBV Technologies Cut by Lifesci Capital
HC Wainwright Predicts Reduced Earnings for DBV Technologies
FOUR TRILLION DOLLARS!
Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft. But one controversial analyst, known for predicting the collapses of Fannie Mae, GM, and others, is issuing a serious warning. He believes Nvidia’s rise has masked a dangerous flaw—and that the stock could fall 50% or more from current levels.
See More DBV Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email.

About DBV Technologies

DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

View DBV Technologies Profile

More Earnings Resources from MarketBeat